SpringLeaf Therapeutics, a Boston, MA-based developer of therapies that combine novel and existing pharmaceuticals with a proprietary self-contained subcutaneous delivery system, has closed a $15m Series B financing.
The round was led by new investor SR One, with participation from existing investors Flybridge Capital Partners and North Bridge Venture Partners.
In conjunction with the funding, Brian M. Gallagher, Jr., Ph.D., Partner at SR One, will join SpringLeaf’s board of directors.
According to President and CEO Frank Bobe, Ph.D., the company intends to use the funds to advance its proprietary program. SpringLeaf platform is designed to enable more effective, better tolerated and cost-efficient therapies, and help differentiate existing biopharmaceutical therapies.